Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 3/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17338937 | 1.00 | ADORA2A (0.36) | ADORA2ACYP11B2CPB2JAK1PLAU | |
| SCHEMBL17342221 | 0.86 | CPB2 (0.31) | CPB2 | |
| SCHEMBL17342219 | 0.82 | ADRA1A (0.31) | — | |
| SCHEMBL18762252 | 0.82 | ADRA1A (0.31) | — | |
| SCHEMBL18762250 | 0.82 | ADRA1A (0.31) | — | |
| SCHEMBL20337727 | 0.74 | CYP11B2 (0.40) | ADORA2ACYP11B2CPB2PI4KAPI4K2B | |
| SCHEMBL17338953 | 0.73 | ADORA2A (0.32) | ADORA2APLAUPI4KAPI4K2BPI4K2A | |
| SCHEMBL17338950 | 0.73 | ADORA2A (0.32) | ADORA2APLAUPI4KAPI4K2BPI4K2A | |
| SCHEMBL23852419 | 0.63 | HCAR1 (0.37) | ADORA2ACPB2JAK1PI4KAPI4K2B | |
| SCHEMBL1542827 | 0.63 | ADORA2A (0.32) | ADORA2ACPB2PLAUPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154976-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3154976-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10100064-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20170114078-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114078-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114078-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2015188369-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015188369-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114078-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | ADORA2A 82/4885CYP11B2 774/4885CPB2 2468/4885 |
| US-10100064-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | ADORA2A 82/4885CYP11B2 774/4885CPB2 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.